Login to Your Account



Alemtuzumab a Blockbuster in MS?

Buyout Value Debate Goes on Despite 5-Year Campath Data

By Jennifer Boggs


Friday, October 15, 2010
Genzyme Corp. reported promising five-year data from its Phase II extension study of alemtuzumab in relapsing-remitting multiple sclerosis (MS), news that could bode well for CD52-targeting drug as it looks to compete in the estimated $14 billion MS market. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription